Literature DB >> 23064017

Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Jason Moore1, Amy Jayne McKnight, Bernd Döhler, Matthew J Simmonds, Aisling E Courtney, Oliver J Brand, David Briggs, Simon Ball, Paul Cockwell, Christopher C Patterson, Alexander P Maxwell, Stephen C L Gough, Gerhard Opelz, Richard Borrows.   

Abstract

The impact of variation within genes responsible for the disposition and metabolism of calcineurin inhibitors (CNIs) on clinical outcomes in kidney transplantation is not well understood. Furthermore, the potential influence of donor, rather than recipient, genotypes on clinical endpoints is unknown. Here, we investigated the associations between donor and recipient gene variants with outcome among 4471 white, CNI-treated kidney transplant recipients. We tested for 52 single-nucleotide polymorphisms (SNPs) across five genes: CYP3A4, CYP3A5, ABCB1 (MDR1; encoding P-glycoprotein), NR1I2 (encoding the pregnane X receptor), and PPIA (encoding cyclophilin). In a discovery cohort of 811 patients from Birmingham, United Kingdom, kidney donor CC genotype at C3435T (rs1045642) within ABCB1, a variant known to alter protein expression, was associated with an increased risk for long-term graft failure compared with non-CC genotype (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.20-2.40; P=0.003). No other donor or recipient SNPs were associated with graft survival or mortality. We validated this association in 675 donors from Belfast, United Kingdom (HR, 1.68; 95% CI, 1.21-2.32; P=0.002), and in 2985 donors from the Collaborative Transplant Study (HR, 1.84; 95% CI, 1.08-3.13; P=0.006). In conclusion, these data suggest that an ABCB1 variant known to alter protein expression represents an attractive candidate for future study and risk stratification in kidney transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064017      PMCID: PMC3482733          DOI: 10.1681/ASN.2012030260

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  39 in total

1.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

2.  The renal papilla is a niche for adult kidney stem cells.

Authors:  Juan A Oliver; Omar Maarouf; Faisal H Cheema; Timothy P Martens; Qais Al-Awqati
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

Review 3.  Calcineurin inhibitor nephrotoxicity.

Authors:  Maarten Naesens; Dirk R J Kuypers; Minnie Sarwal
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

4.  Predicting subsequent decline in kidney allograft function from early surveillance biopsies.

Authors:  Fernando G Cosio; Joseph P Grande; Hani Wadei; Timothy S Larson; Matthew D Griffin; Mark D Stegall
Journal:  Am J Transplant       Date:  2005-10       Impact factor: 8.086

5.  Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.

Authors:  K S Lown; R R Mayo; A B Leichtman; H L Hsiao; D K Turgeon; P Schmiedlin-Ren; M B Brown; W Guo; S J Rossi; L Z Benet; P B Watkins
Journal:  Clin Pharmacol Ther       Date:  1997-09       Impact factor: 6.875

6.  Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L S Fung; Philip J O'Connell; Jeremy R Chapman; Richard D M Allen
Journal:  Transplantation       Date:  2004-08-27       Impact factor: 4.939

7.  Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients.

Authors:  Séverine Crettol; Jean-Pierre Venetz; Massimiliano Fontana; John-David Aubert; Nicolas Ansermot; Marc Fathi; Manuel Pascual; Chin B Eap
Journal:  Pharmacogenet Genomics       Date:  2008-04       Impact factor: 2.089

8.  Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity.

Authors:  Melanie S Joy; Susan L Hogan; Bawana D Thompson; William F Finn; Volker Nickeleit
Journal:  Nephrol Dial Transplant       Date:  2007-03-29       Impact factor: 5.992

9.  CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine.

Authors:  R Kreutz; J Bolbrinker; F van der Sman-de Beer; E W Boeschoten; F W Dekker; S Kain; P Martus; A Sietmann; F Friedrichs; M Stoll; G Offermann; J Beige
Journal:  Pharmacogenomics J       Date:  2008-01-08       Impact factor: 3.550

10.  Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.

Authors:  Mary F Hebert; Amy L Dowling; Cynthia Gierwatowski; Yvonne S Lin; Karen L Edwards; Connie L Davis; Christopher L Marsh; Erin G Schuetz; Kenneth E Thummel
Journal:  Pharmacogenetics       Date:  2003-11
View more
  25 in total

Review 1.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 2.  Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

Authors:  Laure Elens; Rachida Bouamar; Nauras Shuker; Dennis A Hesselink; Teun van Gelder; Ron H N van Schaik
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 3.  APOL1 and nephropathy progression in populations of African ancestry.

Authors:  Barry I Freedman
Journal:  Semin Nephrol       Date:  2013-09       Impact factor: 5.299

Review 4.  Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.

Authors:  Teun van Gelder; Ron H van Schaik; Dennis A Hesselink
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

Review 5.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 6.  The impact of APOL1, CAV1, and ABCB1 gene variants on outcomes in kidney transplantation: donor and recipient effects.

Authors:  Amudha Palanisamy; Amber M Reeves-Daniel; Barry I Freedman
Journal:  Pediatr Nephrol       Date:  2013-06-09       Impact factor: 3.714

Review 7.  Kidney Fibrosis: Origins and Interventions.

Authors:  Thomas Vanhove; Roel Goldschmeding; Dirk Kuypers
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

Review 8.  Apolipoprotein L1 Gene Effects on Kidney Transplantation.

Authors:  Barry I Freedman; Jayme E Locke; Amber M Reeves-Daniel; Bruce A Julian
Journal:  Semin Nephrol       Date:  2017-11       Impact factor: 5.299

9.  Genetic determinants of renal transplant outcome: where do we stand?

Authors:  Paul J Phelan; Peter J Conlon; Matthew A Sparks
Journal:  J Nephrol       Date:  2014-02-11       Impact factor: 3.902

10.  Role of pharmacogenomics in dialysis and transplantation.

Authors:  Kelly Birdwell
Journal:  Curr Opin Nephrol Hypertens       Date:  2014-11       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.